Cargando…
Are biologics more effective than classical disease-modifying antirheumatic drugs?
Major achievements have been reached in the treatment of rheumatoid arthritis during past decades due to the recognition of methotrexate as an anchor drug for treatment of rheumatoid arthritis, due to the notion of a treatment window of opportunity in patients with recent-onset rheumatoid arthritis...
Autores principales: | Nurmohamed, Michael T, Dijkmans, Ben AC |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592779/ https://www.ncbi.nlm.nih.gov/pubmed/18828888 http://dx.doi.org/10.1186/ar2491 |
Ejemplares similares
-
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study
por: van Halm, Vokko P, et al.
Publicado: (2006) -
Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
por: Jansen, G, et al.
Publicado: (2002) -
Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021) -
Premise: traditional disease-modifying antirheumatic drugs are less effective and safe than targeted therapy with biologic response modifiers in rheumatoid arthritis
por: Fleischmann, R
Publicado: (2003) -
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)